HAEHealthcare · Medical DevicesThe 11 Wall Street analysts covering Haemonetics Corp. hold a median 12-month price target of $96 — +9.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 99 of 100 as at 10 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Haemonetics Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (97): The share count has been shrinking and the company is not leaning on new borrowing.
Growth (45): Sales and profits are flat, shrinking, or growing more slowly than they were.
Size (27): Larger than most of the companies we track — more scrutinised, less often mispriced.
The bullish and bearish analyst opinions on HAE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +9.5% from it.
Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Aug 2026 | Citigroup | Maintains | Neutral | $79 → $92 |
| 7 Aug 2026 | JP Morgan | Maintains | Neutral | $62 → $86 |
| 6 Aug 2026 | BTIG | Maintains | Buy | $84 → $96 |
| 15 July 2026 | Mizuho | Maintains | Outperform | — |
| 15 July 2026 | Mizuho | Maintains | Outperform | $85 → $90 |
| 26 June 2026 | BTIG | Reiterates | Buy | $84 |
| 26 June 2026 | BTIG | Reiterates | Buy | — |
| 17 June 2026 | BTIG | Reiterates | Buy | — |
| 15 June 2026 | Mizuho | Maintains | Outperform | — |
| 28 May 2026 | Citigroup | Maintains | Neutral | — |
| 22 May 2026 | B of A Securities | Upgrade | Buy | — |
| 12 May 2026 | Barrington Research | Maintains | Outperform | — |
| 8 May 2026 | JP Morgan | Maintains | Neutral | — |
| 13 Apr 2026 | Mizuho | Maintains | Outperform | — |
| 7 Apr 2026 | Citigroup | Maintains | Neutral | — |
| 11 Mar 2026 | Citigroup | Maintains | Neutral | — |
| 6 Feb 2026 | Barrington Research | Maintains | Outperform | — |
| 6 Feb 2026 | BTIG | Reiterates | Buy | — |
| 6 Feb 2026 | Citigroup | Maintains | Neutral | — |
| 6 Feb 2026 | Mizuho | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HAE appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 18% of US stocks
Cheaper than 42% of US stocks
Cheaper than 22% of US stocks
Cheaper than 27% of US stocks
Higher than 41% of US stocks
Higher than 33% of US stocks
Higher than 73% of US stocks
Higher than 77% of US stocks
Higher than 65% of US stocks
Higher than 66% of US stocks
Higher than 84% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
The rank is the raw material. Whether the rules would actually own Haemonetics Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks examines Haemonetics' reliance on international sales and what its international revenue patterns may imply for Wall Street forecasts and the company's prospective stock trajectory.
Why it matters — A HAE watcher would care because the company's international revenue exposure can influence analyst forecasts and the outlook for the stock.
Haemonetics reported a stronger start to fiscal 2027, with first-quarter revenue up 6% year over year to $339 million and adjusted diluted EPS up 4% to $1.14. The company raised its full-year revenue outlook, citing broad-based growth across its MedSurg and apheresis businesses while maintaining a disciplined stance on assumptions for the remainder of the year.
Why it matters — For HAE watchers, the positive first-quarter results and raised full-year revenue outlook indicate strengthening momentum across the company's core businesses.
Seeking Alpha published the transcript of Haemonetics Corporation's Q1 2027 earnings call. The item announces the availability of the call's transcript for the company's first-quarter fiscal 2027 results.
Why it matters — A Haemonetics watcher would care because the earnings call transcript offers direct insight into management's discussion of the company's first-quarter fiscal 2027 performance.
Haemonetics reported quarterly earnings of $1.14 per share, exceeding the Zacks Consensus Estimate of $1.07 per share and up from $1.10 per share a year ago. The company also topped revenue estimates for the quarter.
Why it matters — The earnings and revenue beats indicate Haemonetics performed better than analyst expectations in its latest quarter, which is relevant for investors tracking the company's financial results.
Haemonetics announced that its first quarter fiscal 2027 financial results, for the period ended June 27, 2026, are available on its Investor Relations website. The company will host a conference call and webcast with investors and analysts to discuss the results at 8:00 a.m.
Why it matters — This item matters to HAE watchers because it marks the release of the company's latest quarterly financial results and gives access to the related materials and analyst call.
The 11 Wall Street analysts covering Haemonetics Corp. have a median 12-month price target of $96, with estimates ranging from $86 to $105. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 11 analysts covering Haemonetics Corp., 8 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Haemonetics Corp. 99 out of 100 across roughly 4,600 US stocks as at 10 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 10 Aug 2026, Haemonetics Corp. ranks 99 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (97 of 100).
No one can know that. What the data says: the median 12-month target from 11 analysts implies +9.5% from the last close, and Ticker Nerd's factor model ranks Haemonetics Corp. 99 out of 100 as at 10 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Haemonetics Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HAE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $86 to $105 over the next 12 months.
Haemonetics Corp. returned +66.2% over the 12 months to 11 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Haemonetics Corporation is a global healthcare company dedicated to providing innovative blood management solutions for organizations around the world. The company plays a crucial role in the healthcare industry by offering devices and services that aim to improve the quality, efficiency, and safety of blood supply.
The most recent item we track (Zacks Investment Research, 11 Aug 2026): "Haemonetics (HAE) Reliance on International Sales: What Investors Need to Know". Zacks examines Haemonetics' reliance on international sales and what its international revenue patterns may imply for Wall Street forecasts and the company's prospective stock trajectory.
Haemonetics Corporation is a global healthcare company dedicated to providing innovative blood management solutions for organizations around the world. The company plays a crucial role in the healthcare industry by offering devices and services that aim to improve the quality, efficiency, and safety of blood supply. Haemonetics is known for its comprehensive portfolio, which includes blood collection and processing systems, plasma collection devices, and software solutions for blood centers and hospitals. The core focus of Haemonetics' offerings lies in enhancing blood donor and patient care, optimizing blood banks' operations, and ensuring the safety and availability of blood and blood components. It serves a wide array of sectors, including hospitals, blood centers, and plasma collection centers, facilitating the global demand for transfusion medicine. With its headquarters in Boston, Massachusetts, Haemonetics continues to influence the landscape of healthcare through its commitment to innovation and its significant contributions to enhancing blood management practices. By catering to a vital segment of the healthcare system, Haemonetics Corporation supports the delivery of essential medical treatments and therapies worldwide.
CEO Mr. Christopher A. Simon · 3,009 employees · United States · https://www.haemonetics.com